about ucb

International Women’s Day 2025: Accelerate Action

Andrea_Puletto — Fri, 07 Mar 2025 12:49:54 +0000

International Women’s Day 2025: Accelerate Action

Marie Teil, Special Patient Populations

Andrea_Puletto Fri 07/03/2025 - 13:49

International Women's Day is more than a celebration; it is a global call to #AccelerateAction and to acknowledge strategies, resources and activities that positively impact women's advancement. At ��ֳ�, we embrace this wholeheartedly, particularly when it comes to ensuring that women of childbearing age have equitable access to clinical research and, ultimately, the best possible care.

Historically, women, particularly those of childbearing age, pregnant, or breastfeeding, have been underrepresented in clinical trials. This gap in research has significant implications, limiting understanding of how treatments affect these populations and leaving many women without clear information on the risks and benefits of their medications.i It is imperative that we #AccelerateAction to address these disparities and drive meaningful change in clinical research, ensuring women are adequately represented.

In the past year, we’ve delved deeper into the experiences of women of childbearing age living with chronic diseases, shedding light on critical gaps in their healthcare journey. Through a social listening study analyzing over 1.2 million posts from France, Germany, Italy, Spain, the UK and the USA, we identified 2,600 posts from women navigating pregnancy and chronic illness. The results of the analysis highlighted four key areas of unmet need: lack of patient support, inadequate specialist discussions, suboptimal coordination of care pathways and the greater need for empowering these patient populations. We concluded that to bridge these gaps, ongoing collaboration is essential to:

Establish moderated online and in-person support services to reduce misinformation and provide platforms for communication between patients and healthcare professionals
Develop educational resources for patients and healthcare professionals
Create tools to enable discussion between women of childbearing age with chronic diseases and their healthcare professionals.

These partnerships and actions are instrumental in driving forward our shared goals so that all women have access to evidence-based healthcare. Collaboration is key to accelerating action. We are proud to partner with patient communities, scientific communities, regulators and policymakers to promote the inclusion of women in clinical trials. Within our work supporting women living with chronic diseases during their reproductive years, we successfully collaborated with the Epilepsy Foundation, HS Connect, IFPA, MG Holistic Society, Living Well with Epilepsy and Lupus Europe to support the development of a discussion guide to promote open discussions about reproductive health between these women and their healthcare professional. It includes background information and key conversation starters to support these discussions to help everyone involved prepare for the future. To read more, visit: /sites/default/files/2024-12/20598_��ֳ�_WoCBA_Discussion_guide%20B_AW0_0.pdf

Looking to the year ahead, the ICH E21 Guideline for Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials is expected to be available for public comment later this year. Additionally, we look forward to continued collaboration with the BRIDGE Commission (Better Research, Information and Data Generation for Empowerment) to provide administrative and communications support.

In my role at ��ֳ�, I am personally committed to this cause. I believe that by working together to champion the inclusion of women in clinical trials, we are not only advancing scientific knowledge but also honoring the fundamental principles of health equity.

On this International Women's Day, let us unite in our efforts to create a world where women receive the care and treatment they deserve. Together, we can make a lasting impact on women's health and wellbeing.

Follow me, @MarieTeil, on LinkedIn, and stay connected with ��ֳ�’s social channels for ongoing updates on our progress.

about ucb

73 Likes

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Andrea_Puletto — Thu, 28 Nov 2024 08:53:01 +0000

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Veronique Toully, Sustainability, Corporate Affairs and Risks

Andrea_Puletto Thu 28/11/2024 - 09:53

Today, I am proud to announce that our new carbon emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi), a significant achievement that underscores our commitment to sustainable impact and our dedication to reducing our environmental footprint.

Specifically, our validated net-zero targets aim to reduce absolute scope 1, 2 and 3 greenhouse gas (GHG) emissions by 90% by 2045 (from our 2019 baseline), ensuring we are aligned with the latest climate science to meet the goals of the Paris Agreement and achieving net-zero before 2050.

This is an important step in a collection of actions we are taking to minimise our environmental footprint. We have started and will continue to embed green aspects and considerations from the very start of the creation of each of our medicines. And we are working closely with our suppliers to set and validate science-based targets for carbon emissions, supporting their shift towards a low-carbon economy.

At ��ֳ� we understand the intrinsic link between the health of people and the planet and believe that the pharmaceutical industry has a critical role to play. Healthcare systems have a large carbon footprint, accounting for an estimated 4.4% of global greenhouse gas emissions, and of those about 1/3 comes from medicines.

We are committed to demonstrating that business success and environmental stewardship are not mutually exclusive but rather mutually reinforcing. Setting science-based targets ensures our growth is sustainable by reducing costs, boosting investor confidence and enhancing our competitiveness and innovation. Sustainability is at the core of our operations, driving us to positively impact society and secure ��ֳ�'s long-term success.

This validation by the SBTi is the testament to the collective work and achievements in our environmental sustainability journey so far. It represents a pivotal moment, elevating our commitment towards a more sustainable future. Together, with the support of our colleagues, partners and stakeholders, we can achieve our vision of creating a healthier, more sustainable world.

“Climate change is one of the biggest challenges facing our planet today, causing devastating impacts such as extreme weather events, sea level rise, and loss of biodiversity. Achieving net-zero emissions is crucial in mitigating the climate crisis. We firmly believe that it is our responsibility to lead by example and take concrete steps towards a sustainable and resilient future. By setting ambitious, science-based targets, we aim to significantly reduce our carbon footprint and contribute to global efforts to mitigate the climate crisis.” Our CEO, Jean-Christophe Tellier, said. 

We invite you to join us on our journey toward a sustainable future. Stay connected and learn more about our initiatives by following me and ��ֳ� on LinkedIn and visiting our website at Reducing emissions | ��ֳ�.

about ucb

innovation sustainability our company

229 Likes

Exciting updates to ��ֳ�'s corporate website, www.ucb.com

Vandenbruaene Nathalie — Wed, 27 Nov 2024 13:13:31 +0000

Exciting updates to ��ֳ�'s corporate website, www.ucb.com

Nathalie Vandenbruaene, Corporate Communication

Vandenbruaene … Wed 27/11/2024 - 14:13

We are thrilled to share some exciting news about ��ֳ�’s digital presence. Our corporate website, ucb.com, has undergone a revamp to better align with our strategic priorities and enhance user experience.

This transformation reflects our commitment to staying at the forefront of digital innovation and ensuring we remain accessible and engaging for all our stakeholders.

Why a revamp?

Alignment with strategy: it is vital that our website mirrors ��ֳ�’s overarching strategy, ensuring relevance to our target audiences and offering a cohesive user experience
Reputation: a sleek, modern website acts as a window to our company’s values, which is crucial for maintaining and enhancing our external reputation
Outdated structure: our previous website setup was a bit complex, making navigation sometimes challenging. An intuitive and user-friendly structure is essential, as our website often serves as the first interaction point with ��ֳ�
Content and design optimization: the website structure has been streamlined and the content has been reorganized. The design elements have also been improved to boost usability and engagement opportunities while maintaining consistency and avoiding redundancy.

What’s next?

The work doesn’t stop here, we will:

Monitor and test: regular monitoring and user testing will ensure the website continues to meet user needs effectively
Explore New Functionalities: we will seek out new features to enhance the site’s attractiveness and functionality.

Take a moment to explore the updated website ucb.com.

Your insights are valuable. Please feel free to reach out via the “Leave a comment” box below or email us with any feedback or comments you may have.

about ucb

website

Comment:

Posted by Vandenbruaene …, 28 November 2024

TEST TEST test

135 Likes

Closing gaps in HS care through community engagement and scientific innovation

Borysiuk Viktor (External) — Wed, 20 Nov 2024 10:25:57 +0000

Closing gaps in HS care through community engagement and scientific innovation

Rhonda Peebles, Dermatology US

Borysiuk Vikto… Wed 20/11/2024 - 11:25

This past summer, ��ֳ� welcomed members of the hidradenitis suppurativa (HS) community – dozens of people living with HS, caregivers, advocacy groups, and medical experts – onto our Atlanta campus for our HS Summit to advance understanding of the treatment journey and unmet needs of those impacted by this disease.

It was incredibly powerful to hear patient testimony firsthand throughout the weekend. I was struck by the openness and honesty of the community as they shared their physical and emotional struggles and the importance of speaking up. Engaging with the HS community and witnessing their strength and perseverance is one of the most rewarding and inspiring parts of my job at ��ֳ�.

Hearing insights and experiences from the HS community have encouraged our drive to bring a new treatment option to people living with this painful, chronic inflammatory skin condition. Today, I’m excited and proud that dermatologists have more options than ever to effectively manage HS.

Our efforts to support both patients and clinicians are ongoing and go far beyond treatment. One big initiative is supporting a registry of HS patients in partnership with the University of California San Francisco (UCSF), which will facilitate research of this disease through collaboration between investigators, clinicians, patients, and industry to improve the lives of people living with HS. We are also proud to sponsor the HS Papaya app, which was developed by two leading HS physicians to help people living with HS track their symptoms and communicate those to their provider, connect with an HS center of excellence, and more. And at the recent Symposium on Hidradenitis Suppurativa Advances (SHSA) conference, we shared new HS data and met with key third party medical and patient advocacy organizations to advance our collaborative initiatives. These are just a few of the things we’re doing as we aim to establish leadership in HS and dermatology.

As advocacy leader Brindley Brooks, co-founder and president of HS Connect, said at the HS Summit, “There’s never a good time to have HS, but there’s never been a better time to have HS.” I am inspired each day as I work alongside those with such a dedication to improving the lives of people impacted by HS. It is a hopeful time. As we forge forward, I know that there will continue to be more treatment options, awareness, and support resources for HS patients – and I am honored to be part of this new era for HS care.

about ucb

HS dermatology science

115 Likes

World Psoriasis Day 2024: Celebrating the invaluable role of family

Borysiuk Viktor (External) — Tue, 29 Oct 2024 13:07:51 +0000

World Psoriasis Day 2024: Celebrating the invaluable role of family

Snauwaert Adriaan, Immuno Global Communication

Borysiuk Vikto… Tue 29/10/2024 - 14:07

Today, Tuesday, 29th October, marks World Psoriasis Day. For more than a decade, the global community has come together on this day to raise awareness and unite in their support of people living with psoriasis and psoriatic arthritis.

Each year, the International Federation of Psoriasis Associations (IFPA) selects a theme for World Psoriasis Day. This year’s theme, ‘Psoriatic Disease and the Family’, aims to raise awareness of the impact living with psoriasis and psoriatic arthritis can have on both people living with these diseases and their family members.

To mark World Psoriasis Day and this year’s theme, we had the honor of an insightful conversation with Caroline, who lives with psoriasis and psoriatic arthritis.

Diagnosed with plaque psoriasis at age 9, Caroline initially received creams for symptom relief. At 19, she was also diagnosed with psoriatic arthritis. For over twenty years, Caroline struggled to manage both her psoriasis and psoriatic arthritis, which sometimes resulted in extended hospital stays. Caroline’s journey was transformed by the support and encouragement of her dermatologist. This dedication and care made a world of difference in her life. Additionally, by connecting with others who faced similar challenges and actively engaging with patient advocacy groups, Caroline discovered a wealth of knowledge and support. These connections and the community supported her to live well with psoriatic disease.

Our conversation with Caroline emphasized the important role family members can play in helping their loved ones thrive while living with psoriatic disease, offering valuable insights into the power of support and understanding.

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

Psoriasis affects everything. The constant itching, the bleeding, the ugliness of it. Psoriasis dictates everything, and I had to learn to cover it up quite cleverly. I couldn’t wear nice dresses and shorts and would avoid dark jackets.
For a while, I had a futile feeling that nothing could be done. It is only when I look back now that I realize how deeply psoriasis and psoriatic arthritis affected me – I can’t believe that it is only in the last couple of years that I have been able to wear shorts and short sleeves.

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

Family support is really important, particularly the practical support they provide. The itch with psoriasis is terrible, so buying or helping to apply creams and lotions that will tackle this is a really simple way family members can support someone living with psoriasis or psoriatic arthritis. It is also very easy for someone living with these conditions to get despondent with the thought that their psoriasis or psoriatic arthritis is never going to go away; encouragement from family members to see a dermatologist and keep pushing to get the right care can be hugely important in not giving up hope. Outside of the family, I have personally found that having a strong support network of people who have shared experiences of living with psoriasis or psoriatic arthritis has taught me so much – from simply picking up tips to being surrounded by people who know exactly what you are going through.

What support or resources do family members need to deepen their awareness and understanding of the conditions?

Education is empowerment – there is not much family members can do without first educating themselves with the facts. By reading information provided by support groups, family members can arm themselves with knowledge around what psoriasis or psoriatic arthritis is. Additionally, to help family members empathize with their loved ones, I think it is important they hear the realities of living with psoriasis and psoriatic arthritis through patient testimonials.

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

I often hear from people living with chronic psoriasis ‘what is the point of even trying anymore’ – they lose hope when their psoriasis keeps coming back. It gives you comfort to talk to people who know how you’re feeling or have similar experiences, it can be a lifeline. Getting the right doctor, the right diagnosis, the right treatment for you and the right information is so important. Don’t give up. Remember, your support and understanding can make a world of difference providing the strength and hope that family members need to live well with their condition and advocate for themselves.

This World Psoriasis Day, we celebrate the invaluable role of family. We extend our heartfelt gratitude to Caroline for sharing her perspective. Her insights into the potential practical and emotional support that can be provided by family and friends highlight the importance of a strong support network. Together, we aim to raise awareness and deepen understanding of psoriasis and psoriatic arthritis.

about ucb

World Psoriasis Day dermatology Immunology

102 Likes

World Arthritis Day 2024: Informed Choices, Better Outcomes

Andrea_Puletto — Fri, 11 Oct 2024 09:33:47 +0000

World Arthritis Day 2024: Informed Choices, Better Outcomes

Marie Teil, Special Patient Populations

Andrea_Puletto Fri 11/10/2024 - 11:33

On October 12, World Arthritis Day will raise awareness about the realities of living with rheumatic and musculoskeletal diseases (RMDs) and to advocate for better research, education, and patient support. On this day, we are all reminded of our collective responsibility to empower those affected by RMDs – including women and their families who lack concrete data and clear guidance about disease management and treatment, particularly during pregnancy and breastfeeding.

This year’s theme – “Informed Choices, Better Outcomes” – underscores how important it is for people living with RMDs to make informed, evidence-based decisions in partnership with their healthcare teams. Despite the notion that there is an overwhelming amount of information for people with RMDs to access, this is simply not the case for women in their childbearing years who seek robust and relevant data.

So much of my role at ��ֳ� as the Global Head of Women of Childbearing Age has centered around the idea that women need to be protected through research, not from research. We cannot allow women with chronic diseases to be continuously overlooked in clinical research due to perceived liability and risk. Although progress has been made in this space, additional work is needed to create a more balanced view in clinical research.

Supporting World Arthritis Day 2024 and uniting with a global community dedicated to bringing evidence and research to patients is a step in the right direction. There is great power in collaboration, and it begins with facing the challenge head-on and recognizing that there is more work to be done to help improve patient outcomes.

Join us in raising awareness by sharing this post and supporting research initiatives. Together, we can support those living with RMDs and strive for a future where everyone can live their lives to the fullest without fear or uncertainty of how certain disease management decisions will impact them or their families. Thank you for joining us in this important cause.

Follow me, @MarieTeil, on LinkedIn as well as ��ֳ�’s social channels for more updates.

about ucb

arthritis Immunology science World Arthritis Day rheumatic and musculoskeletal diseases RMDs

172 Likes

Broadening global access to epilepsy treatment: an update from Rwanda

Andrea_Puletto — Tue, 08 Oct 2024 08:55:08 +0000

Broadening global access to epilepsy treatment: an update from Rwanda

Tim Verfaille, Social Business Operations

Andrea_Puletto Tue 08/10/2024 - 10:55

I am proud to announce a significant milestone in our mission to broaden access to antiseizure medications in low- and middle-income communities: Levetiracetam ��ֳ� 500 mg is now publicly available and reimbursed for Rwandese people with epilepsy who need this treatment, going a step further after its funding by private insurance schemes since May.

Nearly 80% of people with epilepsy live in low- and middle-income countries (LMIC), where treatment gaps exceed 75% in most low-income countries and 50% in most middle-income countries. Epilepsy remains an important cause of disability and mortality in underserved areas, with many lacking adequate treatment due to constraints such as limited healthcare, unequal resources, a lack of access and awareness as well as stigmatization.

As a company with a rich heritage in epilepsy, with over three decades of expertise in epilepsy research and development, we want to play our part to contribute to possible solutions that address unmet medical needs of people living with epilepsy. This is why we are implementing new business models and approaches to reach underserved people with epilepsy. As part of our social business roadmap, we aim to enhance access to our generic antiseizure treatments in countries with a high prevalence of epilepsy.

Today’s news marks the first time that one of our solutions against epilepsy, that is on the WHO Essential Medicines List since 2023, is having received a marketing authorization by a regulatory authority and is being made available in a sub-Saharan country by ��ֳ�.

In early 2024, we received confirmation from the Rwanda Food and Drugs Authority that Levetiracetam ��ֳ� 500 mg had been registered and approved for use within the country. This medicine is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents over 16 years with newly diagnosed epilepsy. It's also indicated as adjunctive therapy of partial onset seizures with or without secondary generalisation in adults, adolescents, and infants from 1 month of age with epilepsy, in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy, in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Stay tuned for more updates on our commitment to bringing solutions to those who need them most in other underserved communities.

about ucb

Rwanda Access epilepsy antiseizure treatments

Comment:

Posted by Ley Sander , 9 October 2024

Well done, ��ֳ�! You need now to do the same for the rest of Sub-Saharan countries.

Comment:

Posted by Teresa Fogelberg, 14 October 2024

this is very good news indeed. Now monitor progress and dont shy away from broading to other African countries. Why not try neighbour countries or Senegal?

156 Likes

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Andrea_Puletto — Thu, 26 Sep 2024 12:26:46 +0000

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Snauwaert Adriaan, Immunology Global Communication

Andrea_Puletto Thu 26/09/2024 - 14:26

The American Society for Bone and Mineral Research (ASBMR) Annual Meeting is the largest and most comprehensive global congress dedicated to bone, mineral, and musculoskeletal health. Each year, thousands of leading experts, researchers, and clinicians from around the world gather to exchange knowledge and present the latest breakthroughs in disease management, treatment strategies, and scientific innovation. The 2024 meeting promises to continue this tradition of excellence, offering a unique platform for collaboration and discovery in the ever-evolving field of bone health.

This year, ��ֳ� and Amgen will unveil crucial new data that demonstrate significant advancements in reducing fracture risk and improving bone strength, particularly for patients at high risk of osteoporosis-related fractures. These findings will emphasize the value of new therapeutic approaches in comparison to existing treatments, highlighting their potential to transform osteoporosis care and improve long-term outcomes for patients.

At ��ֳ�, we remain dedicated to advancing research and ensuring patients have access to transformative treatments for osteoporosis. Earlier this year, we caught up with experts to discuss the urgent need to address bone health in aging populations and innovation in osteoporosis treatments. These conversations continue at ASBMR 2024, where we look forward to sharing groundbreaking data and collaborating with the global community to drive progress in bone disease management. Watch the video below!

Complementing this is our Fragility Fracture in Focus podcast series which explores how the P4 Health Spectrum (predictive, preventive, personalized, and participatory) – an increasingly recognized cornerstone of proactive modern medicine – looks to shift focus away from disease to the promotion of a state of wellness. Listen NOW to the Fragility Fractures in Focus podcast to find out more! (For healthcare professionals only).

Stay connected for updates throughout the congress, as we continue to push the boundaries of bone health research and patient care.

about ucb

innovation Immunology science

139 Likes

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Vandenbruaene Nathalie — Wed, 25 Sep 2024 07:06:18 +0000

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Eimear O'Brien, Corporate Communications

Vandenbruaene … Wed 25/09/2024 - 09:06

As the European Academy of Dermatology and Venerology (EADV) annual congress approaches, ��ֳ� proudly reaffirms its commitment to advancing immuno-dermatology care. This prestigious event unites leading dermatologists, scientists, and healthcare professionals to share the latest research and address critical unmet needs. We are excited to explore how the scientific advancements showcased at this year’s congress in Amsterdam can enhance our ability to serve people living with dermatological diseases.

��ֳ� stands with the scientific, medical, and patient communities, working together to raise the standard of care in immuno-dermatology. Our participation at EADV reflects our commitment to investing in the science that can enable better outcomes for people living with immune-mediated inflammatory diseases. This year, we are proud to have 23 abstracts accepted across our immuno-dermatology portfolio contributing to the understanding of conditions like psoriasis, psoriatic arthritis (PsA) and hidradenitis suppurativa (HS).

Our exhibition booth this year will serve as an exciting hub for engagement and education. We will share our disease awareness initiatives in HS to deepen understanding of this painful and often debilitating condition. Visitors can also learn about our ongoing research, patient support programs, and our commitment to improving the lives of those affected by dermatological diseases.

As part of our commitment to furthering knowledge and understanding in dermatology, we are hosting two scientific symposia that will delve deeper into psoriasis and HS.

As we look forward to EADV 2024, ��ֳ� remains steadfast in our mission to advance immuno-dermatology care. By collaborating with the scientific and medical communities, and championing research, we are committed to improving patient outcomes.

If you are a healthcare professional attending EADV, join us at our scientific symposia or visit our booth to learn more. We look forward to meeting you in Amsterdam!

about ucb

EADV European Academy of Dermatology and Venereology dermatology Immuno-Dermatology

157 Likes

Paving a better future for people living with Lennox-Gastaut syndrome

Vandenbruaene Nathalie — Mon, 09 Sep 2024 08:26:26 +0000

Paving a better future for people living with Lennox-Gastaut syndrome

Konrad Werhahn, Global Medical Affairs

Vandenbruaene … Mon 09/09/2024 - 10:26

For over 30 years, we have provided solutions that have helped improve the lives of millions of people living with epilepsy. Through both our initiatives and collaborations with partners, we are always striving to use our expertise to make a difference in the lives of people living with epilepsy.

A priority focus area for ��ֳ� is Lennox-Gastaut syndrome (LGS), a rare severe form of epilepsy with a significant burden for patients and families and high unmet medical need.

What is LGS?

LGS affects an estimated one million people worldwide; it is a severe childhood-onset developmental and epileptic encephalopathy (DEE), a group of epilepsies associated with developmental impairment, and characterized by several different seizure types.

People living with LGS often experience drug-resistant seizures, meaning that multiple treatment attempts have failed to help them to minimize seizure burden, which makes the condition extremely difficult to treat. Overall mortality and Sudden Unexpected Death in Epilepsy (SUDEP) are also major concerns for people living with LGS and their loved ones.

The impact of LGS goes beyond seizures and includes cognitive impairment, communication difficulties, psychiatric symptoms, sleep and behavioral challenges, and mobility problems. All of these issues significantly impact both patients’ and caregivers’ quality of life.

Why is there a significant unmet need in LGS?

A ��ֳ�-supported study presented at the 15th European Epilepsy Congress 2024 highlighted the significant burden for people living with LGS in Europe, featuring data from 454 people living with LGS.

The main findings from the study included:

People living with LGS experience both seizure and non-seizure impairments, that become increasingly significant with age
Despite people with LGS on average receiving more than three antiseizure medications each day, only 13% report good or very good quality of life
19% of people with LGS report severe or very severe physical impairment, while 28% report severe or very severe mental impairment

The study authors suggest that these findings point to an unmet need for therapies which can target both drug-resistant seizures and the non-seizure impact of LGS, to improve care for people living with the condition.

The study also found that the mean age of LGS diagnosis (five years old) was roughly a year later than the most common age of seizure onset (four years old). It’s vital that the time to diagnosis is reduced and that we build awareness of LGS to enable earlier intervention to improve outcomes for people living with the condition.

Our commitment to the LGS community

LGS is difficult to diagnose because of the lack of specific biological markers of the condition, multiple possible causes, and varied presentation of symptoms.vi At the European Epilepsy Congress (EEC), ��ֳ� presented details of a new LGS electronic decision-assisting tool based on the International League Against Epilepsy (ILAE) diagnostic criteria. Developed by a group of ten epilepsy experts1, the tool is designed to help physicians evaluate the likelihood that their patient has LGS.

It is hoped the online tool will drive disease awareness and encourage HCPs to consider LGS as a potential cause of the challenges that the patient is facing, potentially accelerating diagnosis and helping families living with LGS to receive the support they need sooner.

The importance of collaboration

Both in LGS and across the epilepsies more broadly, we are reminded of the importance of collaboration and knowledge sharing to build a better future for people living with epileptic conditions.

At ��ֳ�, we are driven to keep pushing forward with scientific innovation to better understand these life-changing conditions, the challenges being faced by the community, and how we can offer improved care to patients, their caregivers, and families. We stand with the epilepsy community and are committed to making a real difference to their lives.

about ucb

LGS Lennox-Gastaut syndrome EEC 2024 European Epilepsy Congress 2024 epilepsy

149 Likes

about ucb

International Women’s Day 2025: Accelerate Action

Leave a Comment

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Leave a Comment

Exciting updates to ��ֳ�'s corporate website, www.ucb.com

Leave a Comment

Closing gaps in HS care through community engagement and scientific innovation

Leave a Comment

World Psoriasis Day 2024: Celebrating the invaluable role of family

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

What support or resources do family members need to deepen their awareness and understanding of the conditions?

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

Leave a Comment

World Arthritis Day 2024: Informed Choices, Better Outcomes

Leave a Comment

Broadening global access to epilepsy treatment: an update from Rwanda

Leave a Comment

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Leave a Comment

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Leave a Comment

Paving a better future for people living with Lennox-Gastaut syndrome

What is LGS?

Why is there a significant unmet need in LGS?

Our commitment to the LGS community

The importance of collaboration

Leave a Comment

about ucb

International Women’s Day 2025: Accelerate Action

Leave a Comment

������ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Leave a Comment

Exciting updates to ������ֳ�'s corporate website, www.ucb.com

Leave a Comment

Closing gaps in HS care through community engagement and scientific innovation

Leave a Comment

World Psoriasis Day 2024: Celebrating the invaluable role of family

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

What support or resources do family members need to deepen their awareness and understanding of the conditions?

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

Leave a Comment

World Arthritis Day 2024: Informed Choices, Better Outcomes

Leave a Comment

Broadening global access to epilepsy treatment: an update from Rwanda

Leave a Comment

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Leave a Comment

������ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Leave a Comment

Paving a better future for people living with Lennox-Gastaut syndrome

What is LGS?

Why is there a significant unmet need in LGS?

Our commitment to the LGS community

The importance of collaboration

Leave a Comment

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Exciting updates to ��ֳ�'s corporate website, www.ucb.com

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology